Dark Matter Blog

APRIL 4, 2023

Prior to 2015, I had a casual relationship, at best, with targeting RNA. The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. Welcome to the RNA world. Familiar tools to solve familiar problems with proteins.

Small Molecule 52

Small Molecule RNA Fragment Screening DNA 52

Sygnature Discovery

SEPTEMBER 12, 2024

Structures solved of many different protein classes, including membrane proteins, protein complexes and recently RNA. With capabilities across X-ray Crystallography Crystallisation/co-crystallisation screening of proteins, DNA, and RNA using in-house and commercial screens at various temperature.

Fragment Screening 52

Fragment Screening RNA Protein Production DNA 52

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we utilise various biophysical technologies to create assays for diverse targets, integral to every stage of the drug discovery process, from hit identification to candidate selection. Covalent drugs may have advantages over non-covalent molecules, such as greater potency and duration of action.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52